204 related articles for article (PubMed ID: 29020515)
1. Manufacturing history of etanercept (Enbrel
Hassett B; Singh E; Mahgoub E; O'Brien J; Vicik SM; Fitzpatrick B
MAbs; 2018 Jan; 10(1):159-165. PubMed ID: 29020515
[TBL] [Abstract][Full Text] [Related]
2. Variability of intended copies for etanercept (Enbrel®): Data on multiple batches of seven products.
Hassett B; Scheinberg M; Castañeda-Hernández G; Li M; Rao URK; Singh E; Mahgoub E; Coindreau J; O'Brien J; Vicik SM; Fitzpatrick B
MAbs; 2018 Jan; 10(1):166-176. PubMed ID: 29020508
[TBL] [Abstract][Full Text] [Related]
3. Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars.
Ebbers HC; Fehrmann B; Ottosen M; Hvorslev N; Høier P; Hwang JW; Chung J; Lim HT; Lee S; Hong J; Rezk MF
BioDrugs; 2020 Apr; 34(2):225-233. PubMed ID: 31925703
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept.
Cho IH; Lee N; Song D; Jung SY; Bou-Assaf G; Sosic Z; Zhang W; Lyubarskaya Y
MAbs; 2016; 8(6):1136-55. PubMed ID: 27246928
[TBL] [Abstract][Full Text] [Related]
5. TNF-α blockade suppresses pericystic inflammation following anthelmintic treatment in porcine neurocysticercosis.
Mahanty S; Orrego MA; Cangalaya C; Adrianzen MP; Arroyo G; Calcina J; Gonzalez AE; García HH; Guerra-Giraldez C; Nash TE;
PLoS Negl Trop Dis; 2017 Nov; 11(11):e0006059. PubMed ID: 29190292
[TBL] [Abstract][Full Text] [Related]
6. Characterization and Application of a Unique Panel of Monoclonal Antibodies Generated against Etanercept.
Detrez I; Brouwers E; Peeters M; Geukens N; de Vlam K; Gils A
J Immunol; 2016 Mar; 196(6):2879-84. PubMed ID: 26843328
[TBL] [Abstract][Full Text] [Related]
7. N-terminus of Etanercept is Proteolytically Processed by Dipeptidyl Peptidase-4.
Masui S; Yonezawa A; Yokoyama K; Iwamoto N; Shimada T; Onishi A; Onizawa H; Fujii T; Murakami K; Murata K; Tanaka M; Nakagawa S; Hira D; Itohara K; Imai S; Nakagawa T; Hayakari M; Matsuda S; Morinobu A; Terada T; Matsubara K
Pharm Res; 2022 Oct; 39(10):2541-2554. PubMed ID: 35986123
[TBL] [Abstract][Full Text] [Related]
8. Diversity in host clone performance within a Chinese hamster ovary cell line.
O'Callaghan PM; Berthelot ME; Young RJ; Graham JW; Racher AJ; Aldana D
Biotechnol Prog; 2015; 31(5):1187-200. PubMed ID: 25918883
[TBL] [Abstract][Full Text] [Related]
9. Establishment of the first WHO International Standard for etanercept, a TNF receptor II Fc fusion protein: Report of an international collaborative study.
Wadhwa M; Bird C; Dilger P; Rigsby P; Jia H; Gross MEB;
J Immunol Methods; 2017 Aug; 447():14-22. PubMed ID: 28288790
[TBL] [Abstract][Full Text] [Related]
10. Anti-drug antibodies in Colombian patients with rheumatoid arthritis treated with Enbrel vs Etanar - Preliminary report.
Reyes-Beltrán B; Delgado G
J Immunotoxicol; 2017 Dec; 14(1):103-108. PubMed ID: 28431492
[TBL] [Abstract][Full Text] [Related]
11. Effects of Etanercept against Transient Cerebral Ischemia in Diabetic Rats.
Iwata N; Takayama H; Xuan M; Kamiuchi S; Matsuzaki H; Okazaki M; Hibino Y
Biomed Res Int; 2015; 2015():189292. PubMed ID: 26665003
[TBL] [Abstract][Full Text] [Related]
12. Pharmaceutical quality by design: product and process development, understanding, and control.
Yu LX
Pharm Res; 2008 Apr; 25(4):781-91. PubMed ID: 18185986
[TBL] [Abstract][Full Text] [Related]
13. Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel(®)).
Hofmann HP; Kronthaler U; Fritsch C; Grau R; Müller SO; Mayer R; Seidl A; Da Silva A
Expert Opin Biol Ther; 2016 Oct; 16(10):1185-95. PubMed ID: 27463856
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor inhibitors block apoptosis of human epithelial cells of the salivary glands.
Sisto M; D'Amore M; Caprio S; Mitolo V; Scagliusi P; Lisi S
Ann N Y Acad Sci; 2009 Aug; 1171():407-14. PubMed ID: 19723083
[TBL] [Abstract][Full Text] [Related]
15. Physicochemical Characterization, Glycosylation Pattern and Biosimilarity Assessment of the Fusion Protein Etanercept.
Montacir O; Montacir H; Springer A; Hinderlich S; Mahboudi F; Saadati A; Parr MK
Protein J; 2018 Apr; 37(2):164-179. PubMed ID: 29411222
[TBL] [Abstract][Full Text] [Related]
16. Quality control and analytical techniques for biopharmaceuticals.
Robinson CJ; Jones C
Bioanalysis; 2011 Jan; 3(1):81-95. PubMed ID: 21175369
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrel®): a double-blind, single-dose, crossover study in healthy volunteers.
Yi S; Kim SE; Park MK; Yoon SH; Cho JY; Lim KS; Shin SG; Jang IJ; Yu KS
BioDrugs; 2012 Jun; 26(3):177-84. PubMed ID: 22515513
[TBL] [Abstract][Full Text] [Related]
18. Real-time product attribute control to manufacture antibodies with defined N-linked glycan levels.
Zupke C; Brady LJ; Slade PG; Clark P; Caspary RG; Livingston B; Taylor L; Bigham K; Morris AE; Bailey RW
Biotechnol Prog; 2015; 31(5):1433-41. PubMed ID: 26179435
[TBL] [Abstract][Full Text] [Related]
19. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.
Griffiths CEM; Thaçi D; Gerdes S; Arenberger P; Pulka G; Kingo K; Weglowska J; ; Hattebuhr N; Poetzl J; Woehling H; Wuerth G; Afonso M
Br J Dermatol; 2017 Apr; 176(4):928-938. PubMed ID: 27787890
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Health Outcomes with Etanercept Treatment in Patients with Early Nonradiographic Axial Spondyloarthritis.
Dougados M; Tsai WC; Saaibi DL; Bonin R; Bukowski J; Pedersen R; Vlahos B; Kotak S
J Rheumatol; 2015 Oct; 42(10):1835-41. PubMed ID: 26276968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
